| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GOVX Stock Overview
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform.
GeoVax Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$4.58 |
| 52 Week Low | US$0.55 |
| Beta | 2.94 |
| 1 Month Change | -19.23% |
| 3 Month Change | -34.26% |
| 1 Year Change | -83.18% |
| 3 Year Change | -96.97% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Sep 08
Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
May 24We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Nov 27We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Aug 14Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?
Feb 18Shareholder Returns
| GOVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 0.4% | 1.3% |
| 1Y | -83.2% | -14.4% | -18.5% |
Return vs Industry: GOVX underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: GOVX underperformed the US Market which returned -18.5% over the past year.
Price Volatility
| GOVX volatility | |
|---|---|
| GOVX Average Weekly Movement | 21.7% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: GOVX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: GOVX's weekly volatility has decreased from 33% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 11 | David Dodd | https://www.geovax.com |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S.
GeoVax Labs, Inc. Fundamentals Summary
| GOVX fundamental statistics | |
|---|---|
| Market Cap | US$20.78m |
| Earnings (TTM) | -US$22.38m |
| Revenue (TTM) | US$246.49k |
84.4x
P/S Ratio-0.9x
P/E RatioIs GOVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOVX income statement (TTM) | |
|---|---|
| Revenue | US$246.49k |
| Cost of Revenue | US$18.25m |
| Gross Profit | -US$18.01m |
| Other Expenses | US$4.37m |
| Earnings | -US$22.38m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | -7,305.27% |
| Net Profit Margin | -9,079.68% |
| Debt/Equity Ratio | 0.0% |
How did GOVX perform over the long term?
See historical performance and comparison